This combination tablet contains Dapagliflozin 10mg, Sitagliptin 100mg, and Metformin Hydrochloride IP 1000mg (Extended Release). It is a potent antidiabetic therapy designed to manage type 2 diabetes mellitus effectively. Dapagliflozin works as an SGLT2 inhibitor, reducing glucose reabsorption in the kidneys, promoting glucose excretion, and helping control blood sugar levels. Sitagliptin is a DPP-4 inhibitor that increases incretin levels, improving insulin secretion and decreasing glucagon release in response to meals. Metformin Hydrochloride ER improves insulin sensitivity, decreases hepatic glucose production, and provides a sustained blood glucose-lowering effect. This triple-action therapy targets multiple pathways of blood sugar regulation, offering better glycemic control, improved HbA1c levels, and reduced risk of diabetes-related complications. The extended-release formulation ensures steady glucose control with reduced dosing frequency and better patient adherence.
